GlassScriptPhysician profile
Jessica Basa
NPI 1447938766
$3,934.16
in general payments reported to CMS, 2019-2025
20 companies · $2,321 in 2025
The $2,321 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $256 · 2024: $1,357 · 2025: $2,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,934.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $828.39 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $593.34 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $585.17 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $432.51 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $234.40 | 2023-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $227.74 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $194.98 | 2023-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $175.69 | 2025 | Qelbree |
| Tempus Ai, INC | $108.83 | 2025 | Tempus Pixel |
| Lundbeck LLC | $108.81 | 2024-2025 | Rexulti |
| Alkermes, INC. | $95.81 | 2024-2025 | Lybalvi, Aristada |
| Collegium Pharmaceutical, INC. | $82.15 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $68.68 | 2024-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $43.81 | 2024-2025 | Trintellix |
| Corium, LLC | $36.61 | 2024 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $25.65 | 2025 | Dyanavel Xr |
| Almatica Pharma LLC | $25.36 | 2025 | Loreev Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.00 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $22.34 | 2024 | Perseris |
| Biogen, INC. | $18.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Basa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.